We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ITP definitions: Time for an update.
- Authors
Ghanima, Waleed; Hill, Quentin A.; Kuter, David J.
- Abstract
Further confounding the concept of "maintenance-free" is that some treatment effects persist after the treatment ends; B-cell depletion may last for months or years after rituximab and splenectomy creates a lifelong disorder of asplenia. In this quest for clarity, whether "response", "durability" or "remission" is the result of ongoing maintenance treatment is relevant given that many ITP therapies such as the TPO-RA may be ongoing. The last 15 years have shown great progress in the management of immune thrombocytopenia (ITP), ranging from the introduction and licensing of two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, to more recently, a Syk tyrosine kinase inhibitor (fostamatinib) and two other TPO-RA (avatrombopag and hetrombopag).
- Subjects
THROMBOPOIETIN receptor agonists; MEDICAL personnel; AUTOIMMUNE hemolytic anemia; IDIOPATHIC thrombocytopenic purpura; ORGANELLE formation
- Publication
British Journal of Haematology, 2023, Vol 201, Issue 5, p1005
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18791